Department of Surgery, University of Hong Kong, Hong Kong, China.
Liver Transpl. 2012 Jul;18(7):779-85. doi: 10.1002/lt.23401.
This study investigated the outcomes of living donor liver transplantation (LDLT) for patients with preoperative type 1 hepatorenal syndrome (HRS) and acute hepatic decompensation. Prospectively collected data for 104 patients who had fulminant hepatic failure, acute decompensation of cirrhosis, or an acute flare of chronic hepatitis B were analyzed. Thirty-three patients (31.7%) had HRS (the HRS group), and 71 patients (68.3%) did not (the non-HRS group). The median follow-up period was 60 months. The HRS group had significantly more preoperative intensive care unit (ICU) admissions (84.8% versus 60.6%, P = 0.01), worse preoperative blood test results (creatinine, 248 versus 88 μmol/L, P < 0.001; total bilirubin, 630 versus 555 μmol/L, P = 0.001), more hemodialysis (48.5% versus 0%, P < 0.001), more blood transfusions (9 versus 4 U, P < 0.001), longer postoperative ICU stays (8 versus 4 days, P < 0.001), worse postoperative blood test results (creatinine at 1 year, 108 versus 96 μmol/L, P = 0.006), and poorer overall survival (P < 0.001). In a multivariate analysis, only HRS was associated with poorer overall survival (hazard ratio = 8.592, 95% confidence interval = 1.782-41.431, P = 0.007). In conclusion, HRS patients had worse postoperative renal function and overall survival than non-HRS patients. However, their 5-year overall survival rate was still nearly 80%, which is satisfactory. Therefore, LDLT can be considered for patients who have acute hepatic decompensation with or without HRS.
本研究调查了术前 1 型肝肾综合征(HRS)和急性肝性失代偿的活体供肝肝移植(LDLT)的结果。分析了 104 例暴发性肝衰竭、肝硬化急性失代偿或慢性乙型肝炎急性发作患者的前瞻性收集数据。33 例(31.7%)患者存在 HRS(HRS 组),71 例(68.3%)患者不存在 HRS(非 HRS 组)。中位随访时间为 60 个月。HRS 组术前 ICU 入住率明显更高(84.8%比 60.6%,P = 0.01),术前血液检查结果更差(肌酐 248 μmol/L 比 88 μmol/L,P < 0.001;总胆红素 630 μmol/L 比 555 μmol/L,P = 0.001),更多患者接受血液透析(48.5%比 0%,P < 0.001),更多患者接受输血(9 比 4 U,P < 0.001),术后 ICU 停留时间更长(8 比 4 天,P < 0.001),术后血液检查结果更差(1 年时肌酐 108 μmol/L 比 96 μmol/L,P = 0.006),总生存率更差(P < 0.001)。多变量分析显示,只有 HRS 与较差的总生存率相关(风险比=8.592,95%置信区间=1.782-41.431,P = 0.007)。总之,HRS 患者术后肾功能和总体生存率均较非 HRS 患者差。然而,他们的 5 年总体生存率仍接近 80%,这是令人满意的。因此,对于伴有或不伴有 HRS 的急性肝性失代偿患者,可以考虑 LDLT。